Alector, Inc. Stock News

Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's disease; both advancing toward IND-enabling studies

Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint

Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mu...

Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Myles Minter - William B...

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's progranulin (PGRN) franchise and Alector Brain Carrier (ABC)–enabled programs.

Alector, Inc. (NASDAQ:ALEC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthc...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2025 (New York, New York) Thurs...